Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/HLA-DQA1_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/HLA-DQA1_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/HLA-DQA1_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/HLA-DQA1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/GC/HLA-DQA1_pca_on_diff_genes.png) | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/HLA-DQA1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/HLA-DQA1_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/HLA-DQA1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/HLA-DQA1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/HLA-DQA1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:002240722 | Breast | DCIS | regulation of cell-cell adhesion | 56/1390 | 448/18723 | 8.53e-05 | 1.61e-03 | 56 |
GO:002240921 | Breast | DCIS | positive regulation of cell-cell adhesion | 39/1390 | 284/18723 | 1.44e-04 | 2.45e-03 | 39 |
GO:005125111 | Breast | DCIS | positive regulation of lymphocyte activation | 42/1390 | 362/18723 | 2.65e-03 | 2.35e-02 | 42 |
GO:002240710 | Cervix | CC | regulation of cell-cell adhesion | 103/2311 | 448/18723 | 1.78e-10 | 2.87e-08 | 103 |
GO:004578510 | Cervix | CC | positive regulation of cell adhesion | 101/2311 | 437/18723 | 1.96e-10 | 3.08e-08 | 101 |
GO:00421108 | Cervix | CC | T cell activation | 107/2311 | 487/18723 | 1.24e-09 | 1.46e-07 | 107 |
GO:00508638 | Cervix | CC | regulation of T cell activation | 80/2311 | 329/18723 | 1.28e-09 | 1.47e-07 | 80 |
GO:00071598 | Cervix | CC | leukocyte cell-cell adhesion | 85/2311 | 371/18723 | 8.27e-09 | 7.07e-07 | 85 |
GO:19030378 | Cervix | CC | regulation of leukocyte cell-cell adhesion | 77/2311 | 336/18723 | 4.08e-08 | 2.54e-06 | 77 |
GO:000247810 | Cervix | CC | antigen processing and presentation of exogenous peptide antigen | 18/2311 | 38/18723 | 1.20e-07 | 6.06e-06 | 18 |
GO:004800210 | Cervix | CC | antigen processing and presentation of peptide antigen | 24/2311 | 62/18723 | 1.21e-07 | 6.07e-06 | 24 |
GO:001988410 | Cervix | CC | antigen processing and presentation of exogenous antigen | 20/2311 | 47/18723 | 2.18e-07 | 9.57e-06 | 20 |
GO:00023968 | Cervix | CC | MHC protein complex assembly | 12/2311 | 19/18723 | 2.65e-07 | 1.12e-05 | 12 |
GO:001988210 | Cervix | CC | antigen processing and presentation | 32/2311 | 106/18723 | 8.61e-07 | 3.08e-05 | 32 |
GO:00025018 | Cervix | CC | peptide antigen assembly with MHC protein complex | 11/2311 | 18/18723 | 1.37e-06 | 4.55e-05 | 11 |
GO:00025048 | Cervix | CC | antigen processing and presentation of peptide or polysaccharide antigen via MHC class II | 16/2311 | 36/18723 | 1.76e-06 | 5.76e-05 | 16 |
GO:00023998 | Cervix | CC | MHC class II protein complex assembly | 10/2311 | 16/18723 | 3.18e-06 | 8.77e-05 | 10 |
GO:00025038 | Cervix | CC | peptide antigen assembly with MHC class II protein complex | 10/2311 | 16/18723 | 3.18e-06 | 8.77e-05 | 10 |
GO:00198869 | Cervix | CC | antigen processing and presentation of exogenous peptide antigen via MHC class II | 14/2311 | 30/18723 | 3.85e-06 | 1.01e-04 | 14 |
GO:00024958 | Cervix | CC | antigen processing and presentation of peptide antigen via MHC class II | 15/2311 | 34/18723 | 4.16e-06 | 1.08e-04 | 15 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0516922 | Breast | IDC | Epstein-Barr virus infection | 45/867 | 202/8465 | 3.16e-07 | 6.05e-06 | 4.52e-06 | 45 |
hsa0414522 | Breast | IDC | Phagosome | 34/867 | 152/8465 | 8.00e-06 | 9.99e-05 | 7.48e-05 | 34 |
hsa0516624 | Breast | IDC | Human T-cell leukemia virus 1 infection | 40/867 | 222/8465 | 2.52e-04 | 2.21e-03 | 1.66e-03 | 40 |
hsa0514012 | Breast | IDC | Leishmaniasis | 16/867 | 77/8465 | 4.35e-03 | 2.57e-02 | 1.92e-02 | 16 |
hsa0532010 | Breast | IDC | Autoimmune thyroid disease | 12/867 | 53/8465 | 6.29e-03 | 3.30e-02 | 2.47e-02 | 12 |
hsa0516932 | Breast | IDC | Epstein-Barr virus infection | 45/867 | 202/8465 | 3.16e-07 | 6.05e-06 | 4.52e-06 | 45 |
hsa0414532 | Breast | IDC | Phagosome | 34/867 | 152/8465 | 8.00e-06 | 9.99e-05 | 7.48e-05 | 34 |
hsa0516634 | Breast | IDC | Human T-cell leukemia virus 1 infection | 40/867 | 222/8465 | 2.52e-04 | 2.21e-03 | 1.66e-03 | 40 |
hsa0514013 | Breast | IDC | Leishmaniasis | 16/867 | 77/8465 | 4.35e-03 | 2.57e-02 | 1.92e-02 | 16 |
hsa0532011 | Breast | IDC | Autoimmune thyroid disease | 12/867 | 53/8465 | 6.29e-03 | 3.30e-02 | 2.47e-02 | 12 |
hsa0516941 | Breast | DCIS | Epstein-Barr virus infection | 46/846 | 202/8465 | 5.60e-08 | 1.13e-06 | 8.33e-07 | 46 |
hsa0461242 | Breast | DCIS | Antigen processing and presentation | 25/846 | 78/8465 | 6.75e-08 | 1.28e-06 | 9.45e-07 | 25 |
hsa0414541 | Breast | DCIS | Phagosome | 35/846 | 152/8465 | 1.67e-06 | 2.45e-05 | 1.81e-05 | 35 |
hsa0541642 | Breast | DCIS | Viral myocarditis | 19/846 | 60/8465 | 3.12e-06 | 4.20e-05 | 3.09e-05 | 19 |
hsa0516642 | Breast | DCIS | Human T-cell leukemia virus 1 infection | 41/846 | 222/8465 | 7.03e-05 | 6.88e-04 | 5.07e-04 | 41 |
hsa0494021 | Breast | DCIS | Type I diabetes mellitus | 13/846 | 43/8465 | 1.91e-04 | 1.72e-03 | 1.27e-03 | 13 |
hsa0533021 | Breast | DCIS | Allograft rejection | 12/846 | 38/8465 | 2.13e-04 | 1.86e-03 | 1.37e-03 | 12 |
hsa0532341 | Breast | DCIS | Rheumatoid arthritis | 21/846 | 93/8465 | 2.64e-04 | 2.24e-03 | 1.65e-03 | 21 |
hsa0533221 | Breast | DCIS | Graft-versus-host disease | 12/846 | 42/8465 | 5.98e-04 | 4.49e-03 | 3.31e-03 | 12 |
hsa0514021 | Breast | DCIS | Leishmaniasis | 17/846 | 77/8465 | 1.29e-03 | 9.06e-03 | 6.67e-03 | 17 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HLA-DQA1 | SNV | Missense_Mutation | | c.151G>C | p.Glu51Gln | p.E51Q | P01909 | protein_coding | deleterious(0.03) | probably_damaging(1) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
HLA-DQA1 | SNV | Missense_Mutation | | c.157G>C | p.Asp53His | p.D53H | P01909 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
HLA-DQA1 | SNV | Missense_Mutation | rs368821483 | c.367N>A | p.Val123Met | p.V123M | P01909 | protein_coding | deleterious(0.01) | benign(0.078) | TCGA-EI-6509-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD |
HLA-DQA1 | SNV | Missense_Mutation | novel | c.352N>C | p.Phe118Leu | p.F118L | P01909 | protein_coding | tolerated(0.4) | benign(0.062) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
HLA-DQA1 | SNV | Missense_Mutation | | c.155N>G | p.Phe52Cys | p.F52C | P01909 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HLA-DQA1 | SNV | Missense_Mutation | | c.621N>T | p.Glu207Asp | p.E207D | P01909 | protein_coding | tolerated(0.1) | benign(0.003) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
HLA-DQA1 | SNV | Missense_Mutation | novel | c.596N>T | p.Pro199Leu | p.P199L | P01909 | protein_coding | deleterious(0.02) | benign(0.426) | TCGA-E6-A1LX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HLA-DQA1 | SNV | Missense_Mutation | novel | c.505N>A | p.His169Asn | p.H169N | P01909 | protein_coding | tolerated(0.19) | possibly_damaging(0.629) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
HLA-DQA1 | SNV | Missense_Mutation | novel | c.481N>G | p.Thr161Ala | p.T161A | P01909 | protein_coding | deleterious(0.02) | possibly_damaging(0.471) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
HLA-DQA1 | SNV | Missense_Mutation | novel | c.727N>A | p.Leu243Met | p.L243M | P01909 | protein_coding | tolerated(0.49) | probably_damaging(0.979) | TCGA-FI-A2F4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |